CN107714647B - Oil-in-water type alizarin nanoemulsion and preparation method thereof - Google Patents
Oil-in-water type alizarin nanoemulsion and preparation method thereof Download PDFInfo
- Publication number
- CN107714647B CN107714647B CN201711139834.0A CN201711139834A CN107714647B CN 107714647 B CN107714647 B CN 107714647B CN 201711139834 A CN201711139834 A CN 201711139834A CN 107714647 B CN107714647 B CN 107714647B
- Authority
- CN
- China
- Prior art keywords
- oil
- alizarin
- surfactant
- nanoemulsion
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 title claims abstract description 109
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 239000004094 surface-active agent Substances 0.000 claims abstract description 46
- 239000004064 cosurfactant Substances 0.000 claims abstract description 23
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 11
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract 2
- 239000003921 oil Substances 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 239000012466 permeate Substances 0.000 abstract description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000273 veterinary drug Substances 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 13
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 229940051841 polyoxyethylene ether Drugs 0.000 description 4
- 229920000056 polyoxyethylene ether Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000123069 Ocyurus chrysurus Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Abstract
The invention belongs to the field of veterinary drugs, and particularly discloses an oil-in-water type alizarin nanoemulsion and a preparation method thereof. The composition comprises the following components in percentage by mass: 0.01-8.0% of alizarin, 13-30% of surfactant, 0-20% of cosurfactant, 2.2-10.0% of oil and the balance of water; wherein the surfactant is tween-80, the cosurfactant is absolute ethyl alcohol, and the oil is isopropyl myristate. The oil-in-water type alizarin nanoemulsion has the characteristics of low viscosity, good stability, strong dispersibility, quick absorption, targeted drug release and the like, and can improve the bioavailability of the drug, prolong the half-life period of the drug in vivo and reduce toxic and side effects; the oil-in-water type alizarin nanoemulsion also has the characteristics of low surface tension and good wettability, so that the medicine can be well attached to bacteria, and can permeate into the bacteria to interfere the metabolism of the bacteria so as to play a role in bacteriostasis or sterilization.
Description
Technical Field
The invention belongs to the field of veterinary drugs, and particularly relates to an oil-in-water type alizarin nanoemulsion and a preparation method thereof.
Background
Alizarin is a substance extracted from a plant madder, which is a long-history plant dye, and is cold in nature and enters the blood system, so that the madder can cool blood and stop bleeding and can remove blood stasis. It is indicated for bleeding due to recklessly blood flow due to blood heat. Cool blood and activate blood, dispel stasis, dredge meridians. Can be used for treating hematemesis, epistaxis, metrorrhagia, traumatic hemorrhage, amenorrhea, blood stasis, arthralgia, and traumatic injury with swelling and pain. Cooling blood to stop bleeding, promoting blood circulation to remove blood stasis: it can stop bleeding without retaining stasis, and is indicated for bleeding due to heat syndrome, amenorrhea and abdominal pain, and traumatic injury.
Alizarin (C) extracted from radix Rubiae14H8O4) Is orange red crystal or ochre yellow powder, has stable property at normal temperature and pressure, and has irritation. The Chinese name is Alizarin and the English name is Alizarin. Alias name: 1, 2-dihydroxy-9, 10-anthracenedione, 1, 2-dihydroxy-1, 2-dihydroxyricinone. Physical and chemical properties, characteristics of orange red crystal or ochre yellow powder, density (g/mL, 20/4 ℃): 1.06; melting Point (. degree. C.): 289.5; boiling point (. degree.C., atmospheric pressure): 430 SU; solubility: readily soluble in hot methanol and 25 ℃ diethyl ether. Can be dissolved in benzene, glacial acetic acid, pyridine, and carbon disulfide, and is slightly soluble in water.
Alizarin has inhibitory effect on the growth of staphylococcus aureus, can inhibit the permeability of connective tissue of rat skin, is similar to rutin, and has anti-inflammatory effect; and it is safe to use, is a cosmetic pigment and a lipstick pigment, and has no side effects. But alizarin has the disadvantages of incomplete absorption, low bioavailability, short half-life in vivo and certain toxicity to the heart because of insolubility in water. Therefore, how to search for a proper dosage form so as to improve the bioavailability, targeting property and slow release property of the alizarin, prolong the half-life period of the alizarin in vivo and enhance the curative effect becomes a problem that the alizarin becomes an antibiotic substitute and is urgently solved.
Disclosure of Invention
The invention aims to provide an oil-in-water type alizarin nanoemulsion and a preparation method thereof.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
an oil-in-water type alizarin nanoemulsion consists of the following components in percentage by mass:
0.01-8.0% of alizarin, 13-30% of surfactant, 0-20% of cosurfactant, 2.2-10.0% of oil and the balance of water; wherein the surfactant is tween-80, the co-surfactant is absolute ethyl alcohol, and the oil is isopropyl myristate (IPM).
The preparation method comprises the following steps:
(1) weighting alizarin, surfactant, cosurfactant, oil and water according to the mass percentage for later use;
(2) completely dissolving alizarin in cosurfactant and surfactant, stirring uniformly, then adding oil, and stirring uniformly; and finally, dripping water, and continuously stirring while dripping until a uniform and transparent system is formed, thereby obtaining the oil-in-water type alizarin nanoemulsion.
The specific use method and dosage of the alizarin nanoemulsion of the invention are as follows: the product is mixed and drunk, 100 mL of the product is added with 65kg of water for livestock and poultry to freely drink, and the product is continuously used for 3 days. Note that: the product is only used for drinking water, but not for injection, and can be used after being mixed with water and not directly used, and the laying period of the laying hens is forbidden.
The invention has the following advantages:
1. the oil-in-water type alizarin nanoemulsion has the characteristics of low viscosity, good stability, strong dispersibility, quick absorption, targeted drug release and the like, and can improve the bioavailability of the drug, prolong the half-life period of the drug in vivo and reduce toxic and side effects;
2. the oil-in-water type alizarin nanoemulsion also has the characteristics of low surface tension and good wettability, so that the medicine can be well attached to bacteria, and can permeate into the bacteria to interfere the metabolism of the bacteria so as to play a role in bacteriostasis or sterilization.
Detailed Description
The technical solution of the present invention is further described in detail with reference to the following specific examples, but the scope of the present invention is not limited thereto.
Example 1
The formula is as follows: 1.2g of alizarin, 6.0g of surfactant, 4.0g of cosurfactant, 2.5g of oil and 13.6g of water; wherein the surfactant is tween-80, the co-surfactant is absolute ethyl alcohol, and the oil is isopropyl myristate (IPM).
The preparation method comprises the following steps:
(1) weighting alizarin, surfactant, oil and water for later use;
(2) completely dissolving alizarin in cosurfactant and surfactant, stirring uniformly, then adding oil, and stirring uniformly; and finally, dripping water, and continuously stirring while dripping until a uniform and transparent system is formed, thereby obtaining the oil-in-water type alizarin nanoemulsion.
Comparative example 1
The formula is as follows: 0.01g of alizarin, 13.38g of surfactant, 2.43g of oil and 84.18g of water; wherein the surfactant is polyoxyethylene ether (40) hydrogenated castor oil (RH 40) and the oil is isopropyl myristate (IPM).
The preparation method comprises the following steps:
(1) weighting alizarin, surfactant, oil and water for later use;
(2) completely dissolving alizarin in a surfactant, uniformly stirring, adding oil, and uniformly stirring; and finally, dripping water, and continuously stirring while dripping until a uniform and transparent system is formed, thereby obtaining the oil-in-water type alizarin nanoemulsion.
Comparative example 2
The formula is as follows: 0.03g of alizarin, 9.0g of surfactant, 1.0g of oil and 20g of water; wherein the surfactant is polyoxyethylene ether (40) hydrogenated castor oil (RH 40) and the oil is isopropyl myristate (IPM).
The preparation method was the same as in comparative example 1.
Comparative example 3
The formula is as follows: 0.3g of alizarin, 9.0g of surfactant, 4.0g of cosurfactant, 1.0g of oil and 25.7g of water; wherein the surfactant is polyoxyethylene ether (40) hydrogenated castor oil (RH 40), the co-surfactant is 1, 2-propanediol, and the oil is isopropyl myristate (IPM).
The preparation method is the same as example 1.
Comparative example 4
The formula is as follows: 0.5g of alizarin, 9.81g of surfactant, 3.27g of cosurfactant, 1.36g of oil and 21.47g of water; wherein the surfactant is polyoxyethylene ether (40) hydrogenated castor oil (RH 40), the co-surfactant is 1, 2-propanediol, and the oil is isopropyl myristate (IPM).
The preparation method is the same as example 1.
Comparative example 5
The formula is as follows: 0.9g of alizarin, 15.0g of surfactant, 5.0g of cosurfactant, 2.2g of oil and 36.9g of water; wherein the surfactant is tween-80, the co-surfactant is absolute ethyl alcohol, and the oil is isopropyl myristate (IPM).
The preparation method is the same as example 1.
Comparative example 6
The formula is as follows: 0.9g of alizarin, 15.0g of surfactant, 5.0g of cosurfactant, 5.0g of oil and 34.1g of water; wherein the surfactant is tween-80, the cosurfactant is absolute ethyl alcohol, and the oil is ethyl oleate.
The preparation method is the same as example 1.
Comparative example 7
The formula is as follows: 0.9g of alizarin, 7.5g of surfactant, 5.0g of cosurfactant, 1.4g of oil and 18.5g of water; wherein the surfactant is tween-80, the co-surfactant is absolute ethyl alcohol, and the oil is isopropyl myristate (IPM).
The preparation method is the same as example 1.
Comparative example 8
The formula is as follows: 1.0g of alizarin, 7.5g of surfactant, 5.0g of cosurfactant, 1.4g of oil and 15.0g of water; wherein the surfactant is tween-80, the co-surfactant is absolute ethyl alcohol, and the oil is isopropyl myristate (IPM).
The preparation method is the same as example 1.
Comparative example 9
The formula is as follows: 1.0g of alizarin, 6.0g of surfactant, 4.0g of cosurfactant, 1.1g of oil and 15.0g of water; wherein the surfactant is tween-80, the cosurfactant is absolute ethyl alcohol, and the oil is ethyl oleate.
The preparation method is the same as example 1.
Comparative example 10
The formula is as follows: 1.2g of alizarin, 7.5g of surfactant, 5.0g of cosurfactant, 1.4g of oil and 15.0g of water; wherein the surfactant is tween-80, the co-surfactant is absolute ethyl alcohol, and the oil is isopropyl myristate (IPM).
The preparation method is the same as example 1.
Comparative example 11
The formula is as follows: 1.3g of alizarin, 6.0g of surfactant, 4.0g of cosurfactant, 1.1g of oil and 9.4g of water; wherein the surfactant is tween-80, the cosurfactant is absolute ethyl alcohol, and the oil is ethyl acetate.
The preparation method is the same as example 1.
Stability test
1. High speed centrifugation test
The prepared alizarin nanoemulsion is put into a centrifuge tube, and the characters of the prepared alizarin nanoemulsion are observed after the alizarin nanoemulsion is centrifuged at the rotating speed of 12000r/min for 20 min, and the results are shown in table 1.
2. Temperature stability test
The prepared alizarin nanoemulsion is filled into a transparent colorless glass bottle, sealed and placed under the conditions of three temperatures of 4 ℃, room temperature (25 ℃) and 60 ℃ for sample observation for 60 days, and the characters of the prepared alizarin nanoemulsion are observed by sampling every 10 days, and the results are shown in tables 2-4.
From the above table, it can be seen that: the nanoemulsion adopting the formula disclosed by the invention keeps clear and transparent no matter subjected to a high-speed centrifugation test or a temperature stability test, and has no unstable demulsification phenomena such as layering, turbidity or crystal precipitation, so that the nanoemulsion is a stable pharmaceutical dosage form. On the contrary, the nanoemulsion obtained by adopting the formula of the comparative example has unstable demulsification phenomenon, turbid or layered solution and unstable system.
Claims (2)
1. An oil-in-water type alizarin nanoemulsion is characterized by comprising the following components in parts by mass:
1.2g of alizarin, 6.0g of surfactant, 4.0g of cosurfactant, 2.5g of oil and 13.6g of water; wherein the surfactant is tween-80, the cosurfactant is absolute ethyl alcohol, and the oil is isopropyl myristate.
2. A method for preparing the oil-in-water type alizarin nanoemulsion of claim 1, comprising the steps of:
(1) weighting alizarin, surfactant, cosurfactant, oil and water for later use according to the mass composition;
(2) completely dissolving alizarin in cosurfactant and surfactant, stirring uniformly, then adding oil, and stirring uniformly; and finally, dripping water, and continuously stirring while dripping until a uniform and transparent system is formed, thereby obtaining the oil-in-water type alizarin nanoemulsion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711139834.0A CN107714647B (en) | 2017-11-16 | 2017-11-16 | Oil-in-water type alizarin nanoemulsion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711139834.0A CN107714647B (en) | 2017-11-16 | 2017-11-16 | Oil-in-water type alizarin nanoemulsion and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107714647A CN107714647A (en) | 2018-02-23 |
| CN107714647B true CN107714647B (en) | 2020-04-10 |
Family
ID=61217037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711139834.0A Active CN107714647B (en) | 2017-11-16 | 2017-11-16 | Oil-in-water type alizarin nanoemulsion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107714647B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102302449A (en) * | 2011-08-25 | 2012-01-04 | 西北农林科技大学 | Oil-in-water cinnamic aldehyde nano emulsion medicament |
| CN104027408A (en) * | 2014-05-14 | 2014-09-10 | 河南牧翔动物药业有限公司 | Oil-in-water type compound apramycin nano-emulsion |
| CN104352566A (en) * | 2014-10-21 | 2015-02-18 | 河南牧翔动物药业有限公司 | Oil-in-water compound chlortetracycline nanoemulsion |
| CN104642312A (en) * | 2015-02-13 | 2015-05-27 | 兰州大学 | Rheum officinale free anthraquinone composition for preventing plant powdery mildew and nano emulsion preparation |
-
2017
- 2017-11-16 CN CN201711139834.0A patent/CN107714647B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102302449A (en) * | 2011-08-25 | 2012-01-04 | 西北农林科技大学 | Oil-in-water cinnamic aldehyde nano emulsion medicament |
| CN104027408A (en) * | 2014-05-14 | 2014-09-10 | 河南牧翔动物药业有限公司 | Oil-in-water type compound apramycin nano-emulsion |
| CN104352566A (en) * | 2014-10-21 | 2015-02-18 | 河南牧翔动物药业有限公司 | Oil-in-water compound chlortetracycline nanoemulsion |
| CN104642312A (en) * | 2015-02-13 | 2015-05-27 | 兰州大学 | Rheum officinale free anthraquinone composition for preventing plant powdery mildew and nano emulsion preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107714647A (en) | 2018-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111298124A (en) | Anti-acne composition containing antibiotics and vegetable oil | |
| US20200146984A1 (en) | Combination of cannabinoids and at least one additional ingredient for the enhancement of therapeutic potency | |
| CN105796370B (en) | Lysotropic liquid crystal precursor and its preparation method and application for root canal disinfection | |
| CN105085452A (en) | Sesquiterpene naphthoquinone compound as well as preparation method and medical application thereof | |
| Sabri et al. | Formulation design and evaluation of anti-microbial activity of emulgel containing essential oil of Myrtus communis L | |
| CN104352566A (en) | Oil-in-water compound chlortetracycline nanoemulsion | |
| CN107714647B (en) | Oil-in-water type alizarin nanoemulsion and preparation method thereof | |
| CN105663102B (en) | A kind of application of phenol amides compound in prevention and treatment cerebral injury | |
| CN108653303A (en) | It is a kind of that there is the high stable type pterostilbene eye drops and preparation method thereof for providing faintly acid Micellar Microenvironment | |
| CN113350427A (en) | Suppository for treating gynecological inflammation and preparation method thereof | |
| CN104274826A (en) | Oil-in-water type compound colistin nanoemulsion | |
| CN101484155A (en) | Naphthalenedione compounds | |
| CN108464968A (en) | A kind of infant's anti-inflammatory cream and preparation method thereof | |
| Derakhshanfar et al. | A Study on the Effects of Perovskia abrotanoides Karel on Experimental Skin Burn in Male Rat: in-vivo and in-vitro Findings | |
| Suara et al. | Neutraceutical and antibacterial properties of methanol extract of Plukenetia conophora [Müll.-Arg. family Euphorbiaceae] leaves and physical properties of its cream formulations | |
| Venkateswarlu | In vitro stability testing of syrup dosage form for hepatitis | |
| JP6538218B2 (en) | Composition for topical application comprising glycerol and tannin | |
| CN105481653A (en) | Cadinane type sesquiterpene compound as well as preparation method and medical application thereof | |
| CN105878179A (en) | Preparation method and application of florfenicol solution | |
| RO128709B1 (en) | Nutritive supplement with hypoglycemic and antioxidant activity and process for preparing the same | |
| CN104274532A (en) | Compound griseofulvin antibacterial medicine | |
| CN108478540B (en) | Preparation method of tripterygium wilfordii slow-release microcapsule | |
| CN107998222A (en) | Beautyberry extract, its preparation method and application | |
| CN101559047A (en) | Function of xylitol erythritol in wound irrigation | |
| Mostafabadi et al. | Antimicrobial effects of Cynara scolymus essential oil: In vitro analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 451162 Airport Road, airport, Henan, Zhengzhou, five Applicant after: HENAN SOAR VETERINARY PHARMACEUTICAL Co.,Ltd. Applicant after: HENAN MUXIANG BIOTECHNOLOGY Co.,Ltd. Address before: 451162 Airport Road, airport, Henan, Zhengzhou, five Applicant before: HENAN SOAR VETERINARY PHARMACEUTICAL Co.,Ltd. Applicant before: HENAN MUXIANG TECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to an oil in water alizarin nano emulsion and a preparation method thereof Effective date of registration: 20211224 Granted publication date: 20200410 Pledgee: China Construction Bank Corporation Zhengzhou Railway Sub Branch Pledgor: HENAN SOAR VETERINARY PHARMACEUTICAL Co.,Ltd.|HENAN MUXIANG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021980016170 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20200410 Pledgee: China Construction Bank Corporation Zhengzhou Railway Sub Branch Pledgor: HENAN SOAR VETERINARY PHARMACEUTICAL Co.,Ltd.|HENAN MUXIANG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021980016170 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A water in oil type Alizarin nanoemulsion and its preparation method Granted publication date: 20200410 Pledgee: China Construction Bank Corporation Zhengzhou Railway Sub Branch Pledgor: HENAN SOAR VETERINARY PHARMACEUTICAL Co.,Ltd.|HENAN MUXIANG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980004821 |